Date: 25/04/2023

Your Name: Susana Hernandez Prieto

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

le sp m ec 6 Pa te	rayment or honoraria for ectures, presentations, peakers bureaus, manuscript writing or ducational events rayment for expert estimony	Roche and ThermoFisher None	Research funding and honorary
6 Pa	nanuscript writing or ducational events ayment for expert estimony upport for attending	None	
6 Pa	ducational events rayment for expert estimony upport for attending	None	
6 Pa	ayment for expert estimony upport for attending	None	
7 Su	estimony upport for attending	None	
7 St	upport for attending		
	+ : / +	None	
m	neetings and/or travel		
	atents planned, issued or	None	
pe	pending		
	articipation on a Data	None	
	afety Monitoring Board or		
	dvisory Board	N	
	eadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	roup, paid or unpaid		
	tock or stock options	None	
12 Re	eceipt of equipment,	None	
	naterials, drugs, medical		
w	riting, gifts or other		
	ervices		
	Other financial or non-	None	
fir	nancial interests		

Research funding and honorary: Roche and ThermoFisherHonorary: Pfizer					

Please place an "X" next to the following statement to indicate your agreement:

Date: 25/04/2023

Your Name: Esther Conde Gallego

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	Pfizer and Takeda	Honorary
	lectures, presentations,	Roche and ThermoFisher	Research funding and honorary
	speakers bureaus,		
	manuscript writing or		
	educational events	N.	
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	None	
	meetings and, or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	None	
13	financial interests	None	
	inianciai interests		

- Research funding and honorary: Roche and ThermoFisher - Honorary: Pfizer and Takeda					

Please place an "X" next to the following statement to indicate your agreement:

Date: 25/04/2023

Your Name: Marta Alonso Martin

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	pranning of the work
2		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	.,	
6	Payment for expert	None	
	testimony		
	_		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

No conflicts of interest.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 18/04/2023

Your Name: Adrián Illarramendi Elósegui

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	.,	
6	Payment for expert	None	
	testimony		
	_		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

No conflicts of interest.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 25/04/2023

Your Name: Helena Bote de Cabo

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	pranning of the work
2		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	.,	
6	Payment for expert	None	
	testimony		
	_		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

No conflicts of interest.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 16-Apr-2023

Your Name: Jon Zugazagoitia

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	BMS, Astra Zeneca and Roche	research funding
3	Royalties or licenses	None	
4	Consulting fees	Astra Zeneca, BMS, Roche	

		and Novartis		
5	Payment or honoraria for	BMS, Roche, Astra Zeneca		
	lectures, presentations,	and Nanostring		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
	testimony			
7	Support for attending	None		
	meetings and/or travel			
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	None		
_				
12	Receipt of equipment,	None		
	materials, drugs, medical			
	writing, gifts or other			
42	services	N.		
13	Other financial or non-	None		
	financial interests			
DI -		auflick of into ! the Col	laudaa hau	
PIE	Please summarize the above conflict of interest in the following box:			

JZ has served as a consultant for Astra Zeneca, BMS, Roche and Novartis, honoraria and travels honoraria from BMS, Roche, Astra Zeneca and Nanostring and research funding from BMS, Astra
Zeneca and Roche.

Please place an "X" next to the following statement to indicate your agreement:

 I certify that I have answered every question and have not altered the wording of any of the questions on this
form.

Date: 18 th April 2023

Your Name: LUIS PAZ-ARES RODRIGUEZ

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past MSD, ASTRAZENECA, PFIZER, BMS	36 months
3	Royalties or licenses	X None	
4	Consulting fees	LILLY, MSD, ROCHE, PHARMAMAR, MERCK,	

		ASTRAZENECA, NOVARTIS, SERVIER, AMGEN, PFIZER, SANOFI, BAYER, BMS, MIRATI, GSK, JANSSEN, TAKEDA, DAICHII	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	ASTRAZENECA, JANSSEN, MERCK, MIRATI	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non- financial interests	X None	

Grants or contracts from any entity: MSD, ASTRAZENECA, PFIZER, BMS

Consulting fees: LILLY, MSD, ROCHE, PHARMAMAR, MERCK, ASTRAZENECA, NOVARTIS, SERVIER, AMGEN, PFIZER, SANOFI, BAYER, BMS, MIRATI, GSK, JANSSEN, TAKEDA, DAICHII

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: ASTRAZENECA, JANSSEN, MERCK, MIRATI

Please place an "X" next to the following statement to indicate your agreement:
X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 24/04/2023

Your Name: Fernando Lopez-Rios

Manuscript Title: A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung

carcinoma

Manuscript number (if known): TLCR-22-855

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	pranning of the work
2		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	Pfizer and Takeda	Honorary
	lectures, presentations,	Roche and ThermoFisher	Research funding and honorary
	speakers bureaus,		The second of th
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Regarding the scope of this work, research funding and honorary from Roche and ThermoFisher and honorary from Pfizer and Takeda.

Please place an "X" next to the following statement to indicate your agreement: